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ABSTRACT 
Background & Aims. Hepatic blood flow (HBF) is best estimated by Fick’s method 
during indocyanine green constant infusion (ICG-HBF) on hepatic vein catheterization. 
We investigated the consistency and agreement of HBF measured by Doppler 
ultrasound (US-HBF) as compared with ICG-HBF in portal hypertensive patients with 
cirrhosis.  
Methods. In 50 patients observed for HVPG measurement (56% compensated; Child 
score 7±2; HVPG 16.6±6.0 mmHg; varices in 75%) US-HBF (Sequoia-512-Acuson; 
4.5-7 MHz convex probe; US-HBF= hepatic artery blood flow + portal vein blood flow) 
and ICG-HBF (Fick’s method after an equilibration period of at least 45 minutes of ICG 
bolus of 5 mg + constant rate infusion of 0.2 mg/min). Intraclass correlation coefficient 
(ICC) for consistency and absolute agreement between US-HBF and ICG-HBF were 
calculated.  
Results. Mean ICG-HBF and US-HBF were similar, being respectively 1004±543 
ml/min, and 994±494 ml/min (p=0.661 vs. ICG-HBF). However, results in individual 
patients disclosed marked differences between the two methods (386±415 ml/min), and 
showed only moderate consistency (ICC 0.456; p<0.0001), absolute agreement (ICC 
0.461; p<0.0001) and linear correlation (R=0.464; p<0.0001). The discrepancy between 
the two methods was maximal in patients with poor liver function, high HBF by any 
technique and more arterialized liver circulation. Hepatic artery blood flow 40% of 
US-HBF indicated with 90% specificity a discrepancy 20% between US-HBF and 
ICG-HBF. 
Conclusions: HBF estimations by Doppler-ultrasound and ICG are significantly 
correlated, but their discrepancy in individual cases is high. Estimation of HBF by 
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Doppler-US should be considered unreliable in patients with poor hepatic function and 
large liver arterialization. 
Abstract word count: 250 
Keywords. Non-invasive methods. Portal hypertension. Hepatic veins. HVPG.  
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INTRODUCTION 
In patients with cirrhosis and portal hypertension the goal of therapy is to reduce portal 
pressure without deteriorating hepatic perfusion [1]. While hepatic venous pressure 
gradient (HVPG) measurement is a consistent and reproducible surrogate of portal 
pressure in cirrhosis [2], there is an unmet need for reliable techniques to assess total 
hepatic blood flow (HBF) in clinical practice.  
The indocyanine green (ICG) constant infusion technique [3] has been widely used to 
estimate HBF by Fick’s method in healthy subjects [4] and in patients with cirrhosis [5, 
6]. This method is objective and reproducible, and is currently considered the gold 
standard for HBF quantitative measurement. However, this technique requires hepatic 
vein catheterization, and cannot be used routinely.  
Given the limitations of ICG-based HBF measurement (ICG-HBF), non-invasive 
methods to estimate HBF have been investigated. Doppler duplex ultrasonography 
(DUS) allows a non-invasive study of abdominal organs and abdominal circulation in 
real time, and has been widely used to assess the circulatory abnormalities occurring in 
patients with cirrhosis and portal hypertension [7, 8]. DUS allows evaluating separately 
the two components of total HBF, namely portal vein blood flow (PBF) and hepatic 
artery blood flow (HABF) [9], but while DUS has been proved reliable for PBF 
estimation [10], very limited and inconclusive data exist on DUS-based measurement of 
total HBF in patients with cirrhosis [11].  
The aim of this study was to assess the consistency and agreement of Doppler 
ultrasound for the assessment of hepatic blood flow in patients with cirrhosis by 
comparing this method with HBF estimated by the gold standard (HBF by ICG by 
Fick’s method during hepatic vein catheterization). 
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METHODS 
This study was approved by the Ethics Committee of Hospital Clinic. The nature of the 
study was explained to the patients, and a written informed consent was obtained in 
each case, according to the principles of the Declaration of Helsinki (revision of 
Edinburgh 2000).  
 
Patients 
50 patients with liver cirrhosis and hepatopetal portal blood flow, with valid 
measurements of ICG-HBF and valid measurements of both PBF and HABF by DUS, 
admitted to our Laboratory for hepatic venous pressure gradient measurement, were 
included in this study. Exclusion criteria were the following: age <18 or >80 years; 
pregnancy; hepatocellular carcinoma; portal vein thrombosis; extraction index of ICG < 
0.1 [5]; insufficient visualization of the portal vein and hepatic artery. This last criterion 
led to the exclusion of 9 patients. 
Tab. 1 shows the main clinical and laboratory characteristics of the studied population. 
 
Hepatic venous pressure gradient and HBF by Indocyanine green (ICG-HBF) 
measurement 
Patients underwent hepatic vein catheterisation in the morning after at least 8 hour 
fasting. Under local anaesthesia, with ultrasonographic guidance (SonoSite Inc, Bothell, 
WA) a 8F venous catheter introducer (Axcess; Maxxim Medical, Athens, TX, USA) 
was placed in the right internal jugular vein using the Seldinger technique. Thereafter, a 
7F balloon-tipped catheter (Edwards Lifesciences, Irvine, CA, USA) was advanced into 
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the right hepatic vein to measure wedged and free hepatic venous pressures (WHVP and 
FHVP, respectively) by the connection to external electro-mechanical transducer and 
polygraph (Mac-Lab®, GE Healthcare, Freiburg, Germany). HVPG was calculated as 
WHVP -FHVP [2].  
 
Preceded by a priming dose of 5 mg, a solution of indocyanine green (Pulsion Medical 
Systems, Munich, Germany) was infused intravenously at a constant rate of 0.2 mg/min. 
After an equilibration period of at least 40 minutes to achieve a steady-state, 4 separate 
sets of simultaneous samples of peripheral and hepatic venous blood were obtained for 
the measurement of hepatic blood flow according to the Fick’s method as previously 
described [12]. To avoid interferences from differences in plasma turbidity, the 
Nielsen’s correction was used [5] at the moment of reading ICG concentration in the 
samples by spectrophotometry (SP-830, Turner Biosystems, Sunnyvale, CA, USA).  
Briefly, ICG clearance was calculated as ICG constant infusion velocity/mean 
concentration of ICG in the peripheral venous blood. ICG extraction index was 
calculated as: (concentration of ICG in the peripheral venous blood – concentration of 
ICG in the hepatic venous blood)/concentration of ICG in peripheral venous blood. 
Hepatic plasma flow was estimated as ICG clearance/ICG extraction index. Finally, 
hepatic blood flow was estimated as: hepatic plasma flow /(1- hematocrit). 
 
HBF by Doppler Ultrasound (US-HBF) 
Patients underwent DUS examination on the same morning of hepatic vein 
catheterization, after an overnight fast, before undergoing the invasive procedure. They 
were invited to lie supine for 10 minutes. Thereafter, Doppler measurements were 
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performed using a Siemens ACUSON Sequoia™ 512 (Acuson, Mountain View, CA, 
USA) ultrasound system, by the same physician in order to avoid interobserver 
variability. A 3.5-5 MHz convex probe provided by a color, power and pulsed Doppler 
software was used. Following current recommendations [7, 8], portal vein and hepatic 
artery were imaged by B-mode. The gain was reduced and the image size made as large 
as possible to improve resolution. Diameter and flow velocity were measured in both 
vessels during short time suspended normal respiration using an oblique scan in the 
epigastrium in a standardized site (crossing of hepatic artery and portal vein). Insonation 
angles of 50-55º were used for these measurements. The Doppler sample was positioned 
in the center of the lumen, setting its dimension as wide as ≥ 50% of the vessel diameter. 
Measurements were taken in triplicate, and the results were expressed as the mean 
value. Variability between different measures was <10%. Intraobserver variability was 
previously assessed and was < 10%. 
 
Time averaged maximum velocity in the portal vein and in the hepatic artery was 
obtained from delineation of the Doppler spectral signal. Portal blood velocity was 
calculated as time averaged maximum velocity multiplied by 0.57, assuming the portal 
velocity profile as parabolic, as previously reported [13, 14]. Similarly, hepatic artery 
velocity was calculated as time averaged maximum velocity multiplied by 0.62, as 
previously reported [7, 8]. 
Portal blood flow (PBF) and hepatic artery blood flow (HABF) were obtained by 
multiplying the portal vein cross-sectional area, assuming a circular shape of the portal 
vein and hepatic artery section, by the mean velocity of blood flow in the vessel [10, 13, 
14] according to the following formula: 
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Blood flow (ml/min) = cross sectional area of the vessel* mean flow velocity (cm/s)*60 
Total hepatic blood flow (US-HBF) was then calculated as PBF + HABF. 
The percentage of US-HBF provided by PBF and HABF was calculated as: PBF/US-
HBF*100 and HABF/US-HBF*100. 
Congestion index of the portal vein was calculated as previously reported by Moriyasu 
et al. [15] as follows:  
Congestion Index= cross-sectional area of the portal vein (cm2)/ portal vein mean flow 
velocity (cm/s). 
 
Statistical analysis 
Means of ICG-HBF and US-HBF were compared by paired T-test or Kruskall-Wallis 
test, while medians were compared by Wilcoxon’s test. Correlations between ICG-HBF 
and US-HBF and its components were made by Pearson’s test. Agreement between the 
two techniques was assessed by intraclass correlation coefficients (ICC) for consistency 
and absolute concordance. According to Landis et al. ICC were interpreted as follows: 
0-0.2 indicates poor agreement: 0.3-0.4 indicates fair agreement; 0.5-0.6 indicates 
moderate agreement; 0.7-0.8 indicates strong agreement; and >0.8 indicates almost 
perfect agreement [16]. 
We arbitrarily defined as “clinically important difference” a difference between US-
HBF and ICG-HBF  20%. Receiver operating characteristics curve (ROC) analysis 
was used to identify the most specific cut-off of the tested parameters able to detect this 
clinically important difference in HBF as compared with ICG-HBF.   
The α value was set at 0.05. All p-values are two-sided. Statistical analysis was 
performed with SPSS 16.0 package (SPSS, Chicago, IL, USA). 
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RESULTS 
Table 2 shows the results of DUS examination, US-HBF and ICG-HBF in the 50 
patients included, and Table 3 shows the correlation of Doppler-US examination with 
HVPG, Child-Pugh score and grade of esophageal varices. As shown, among the 
Doppler-US variables studied, the congestion index of the portal vein significantly 
correlated with the HVPG and with the size of esophageal varices, but did not correlate 
with ICG-HBF (R= − 0.047; p=0.748). 
 Overall, PBF accounted for approximately 70% and HABF for 30% of HBF, as 
estimated by DUS.  
The absolute value of HBF was similar when measured by ICG and by DUS; being 
ICG-HBF 1004±543 (median 827; range 350-3800) and US-HBF 994±494 (median 
894; range 122-3088). The comparison revealed no statistically significant differences 
(p=0.661 for means; p=0.697 for medians). However, despite mean and median values 
being similar, individual patients’ data disclosed marked differences between both 
methods (386±415 ml/min). The discrepancy was “clinically significant” (>20% of the 
total HBF) in 32 patients (64%). Intraclass correlation coefficients between ICG-HBF 
and US-HBF were significant, but only fair: ICC consistency 0.456 (95% CI 0.200-
0.654, p<0.0001); ICC absolute agreement 0.461 (95% CI 0.203-0.658, p<0.0001).  
We next examined which factors could explain the discrepancy between the two 
methods, and found several factors that might have played a role. Firstly, the degree of 
discrepancy increased as HBF measured by any of the methods increased (Kruskall-
Wallis test: p=0.003) (Figure 1 and 2A). Particularly outlier discrepancies were 
observed in patients in whom HBF by either method was over 1900 ml/min, suggesting 
that values over this threshold should not be considered reliable. This occurred in 4 
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patients in our series (8%).  Secondly, a significantly greater discrepancy between the 
two methods was observed in patients with ICG extraction <0.20 (n=17): 633±571 vs. 
274±261 ml/min (p=0.004) in patients with ICG extraction  0.20 (n=33). Patients with 
low ICG extraction, as expected, had  significantly more severe liver failure as 
compared with patients with higher ICG extraction (Child-Pugh score: 9.1±1.4 vs. 
6.0±1.4, p <0.0001; Albumin 29±3 vs. 37±6 g/L, p<0.0001; Bilirubin 3.1±1.1 vs. 
1.2±0.5 mg/dl, p<0.0001; INR 1.58±0.22 vs. 1.21±0.16, p<0.0001). In particular, two of 
the patients with ICG extraction < 0.20 had extremely high, implausible values of HBF 
by ICG (namely 2552 ml/min and 3800 ml/min), suggesting that gross overestimation 
by the gold-standard had probably occurred. Accordingly, we made an exploratory 
analysis restricted to patients with ICG extraction  0.20. In this subgroup, the 
correlation between ICG-HBF and US-HBF improved significantly (R=0.651, 
p<0.0001) (Figure 2B), and so did ICCs: consistency 0.616 (95% CI 0.351-0.790, 
p<0.0001); ICC absolute agreement 0.602 (95% CI 0.336-0.780, p<0.0001).   
The magnitude of the discrepancy between ICG-HBF and US-HBF was also influenced 
by the degree of liver failure as estimated by the MELD score. Patients with MELD 
score > 10 (n=28) had a significantly greater discrepancy than those with MELD 10 
(490±482 Vs 261±288 ml/min; p=0.048).  
  
Correlation between the components of US-HBF and ICG-HBF  
In the whole population we observed a significant correlation between PBF and ICG-
HBF (R=0.459, p<0.001), while HABF and ICG-HBF were not significantly correlated 
(R=0.231, p=0.114). This changed according to compensated or decompensated stage of 
the disease: in compensated patients the correlation between US-HBF and ICG-HBF 
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(R=0.762, p<0.0001) was entirely explained by the correlation of PBF and ICG-HBF 
(R=0.761, p<0.0001), while in decompensated patients it was weaker (R=0.388, 
p=0.050) and explained by HABF (R=0.418, p=0.034) but not by PBF (R=0.185, NS).   
We observed a direct correlation between the magnitude of discrepancy in HBF 
measurement between the two techniques and the proportion of US-HBF provided by 
HABF (R=0.371, p=0.009), which was confirmed in patients with an optimal ICG-HBF 
measurement (those with ICG extraction above 0.20) (R=0.404, p=0.018). This 
observation suggests that arterialization of the liver circulation reduces the accuracy of 
US-Doppler estimations of hepatic blood flow. On ROC curve analysis (Fig. 3), a cut-
off percentage of HABF  40% of total US-HBF had a 90% specificity to detect a 
discrepancy over 20% of US-HBF with ICG-HBF. Patients in whom the HABF was 
less than 40% of total US-HBF had a discrepancy between US-Doppler and ICG-HBF 
of 34±35% as compared with 65±43% in patients in whom the HAF accounted for over 
40% of total HBF (p=0.020). 
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DISCUSSION 
HBF measurement would be ideally needed to investigate the effects of new drugs 
potentially acting on portal hypertension, and to better stratify of the individual risk in 
patients with cirrhosis.  
At first glance, the findings reported in the present paper suggest that ICG-HBF and 
US-HBF give similar results in patients with cirrhosis, as indicated by very close mean 
and median values. However, a closer look at the results shows that the two methods 
have substantial discrepancies in individual patients. We could identify a worse liver 
function (MELD score >10; ICG extraction <0.20), and a higher degree of 
arterialization of the liver circulation as factors increasing the difference of HBF results 
between the two methods. These factors may be used in practice to select the patients 
that can be confidently studied non-invasively by Doppler US. Our results provide 
evidence that Doppler ultrasound measurement of HBF, calculated as the sum of portal 
blood flow and hepatic artery blood flow, might be used as a reasonable non-invasive 
surrogate of the measurement obtained by the invasive gold-standard technique (ICG 
infusion-based estimation) in those patients with cirrhosis and portal hypertension and 
with normal hepatic artery blood flow (HABF by US-Doppler below 35% of total US-
HBF), while patients with a higher arterial component of total hepatic blood flow, as it 
occurs in patients with advanced portal hypertension and extensive portal-systemic 
collaterals, its results should instead be considered insufficiently reliable.  
As any diagnostic technique, the estimation of HBF by Doppler ultrasound has 
advantages and limitations. A clear benefit over ICG-based method is given by the lack 
of invasiveness, by obtaining results in real time, and by the possibility of evaluating 
separately arterial and portal venous supply. In vitro studies demonstrated that US-HBF 
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is accurate and reproducible [9, 17], and age, sex, height, weight and body surface area 
do not modify the accuracy of measurements of PBF by DUS in human subjects [18].  
On the other hand it is well known that Doppler measurements in vivo exhibit a large 
variability which can be due to anatomical (limitations of the angle between the Doppler 
beam and the vessel), physiologic phenomena (e.g. meal ingestion) and to intra- and 
inter-observer errors [19, 20]. While anatomical features cannot be modified, variability 
due to the remaining factors can be minimized by applying standardized protocols of 
examination as suggested by EFSUMB recommendations [8], which were carefully 
adhered to in the present study.  
 
Despite using a careful, standardized protocol for DUS examination [8] we observed 
that the discrepancy between US-HBF (and PBF) by DUS and ICG-HBF increased as 
the value of HBF by any of the two methods increased. This data is in agreement with 
the results obtained by Bolognesi et al. in 27 patients with cirrhosis regarding the 
agreement of PBF by DUS and ICG-HBF [11]. In contrast, we could not reproduce the 
existence of a strong correlation between PBF by DUS and ICG-HBF in the whole 
population we included. This probably depends upon differences in the proportion of 
patients with compensated and decompensated cirrhosis included in the two studies, 
since at a closer look of our data US-HBF and PBF by DUS were well correlated with 
ICG-HBF in patients with well compensated cirrhosis, who were the majority in the 
study by Bolognesi et al [11]. Another major difference with the study by Bolognesi et 
al. [11] regards the availability of data on HABF in our study. 
Our data suggest that while HABF is minimally relevant in terms of correlation with 
ICG-HBF in patients with compensated cirrhosis and preserved liver function, its 
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careful estimation is very important in patients with decompensated cirrhosis and 
advanced liver failure, since in this subset no correlation between PBF by DUS and 
ICG-HBF exists. This supports that hepatic blood flow is largely influenced by HABF 
rather than by PBF in decompensated patients, who very frequently have extensive 
portal-systemic collaterals. This is well in accordance with the fact that, as demonstrated 
by our study, the more arterialized the liver is, the less reliable is the measurement of 
HBF by Doppler, as compared to the gold-standard technique.  
 
Some limitations of our work should be acknowledged. The first is due to the fact that 
HBF estimation by ICG technique is an imperfect gold-standard. The rational for using 
this method is the fact that ICG is primarily non-reversibly extracted by the liver (about 
70%) [21], being HBF the main determinant of its clearance. Nonetheless, it has been 
previously shown that errors in the estimation of HBF by ICG arise when the hepatic 
extraction of the compound is <10%, as it may occur in patients with severe hepatic 
failure. In this paper we excluded this population, and restricted the analysis to patients 
with ICG extraction >0.1; still, two patients with ICG extraction index below 0.2 had 
very high, unlikely values of ICG-HBF, suggesting an estimation error by this 
technique. New methods of liver perfusion estimation, such as the application of 
mathematical models (e.g. dual-inlet two-compartment uptake model) to dynamic 
contrast-enhanced (DCE) magnetic resonance imaging (MRI) using a specific 
hepatobiliary contrast agent (gadoxetic acid) [22], or positron emission tomography 
(PET) using oxygen-15 labeled water [23], might represent better gold-standards for 
future studies, although may be inconvenient for its use in clinical practice. 
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Another limitation is due to our inclusion criteria, which limited the study to patients in 
whom both PBF and HABF could be measured. It was previously reported that hepatic 
artery visualization is possible only in a minority of patients with cirrhosis [9, 11]; this 
was not the case in our series, since both the portal vein and the hepatic artery could be 
assessed in 85% of cases. Advances in the technology applied to ultrasound equipments 
might explain this discrepancy.  
Since only one physician performed all the measurements, interobserver variability was 
not assessed in the present study. However, as previously stated, we applied 
standardized, well accepted protocols of examination [8] which have been previously 
shown to reduce interobserver variability [19, 20]. 
 
Finally, in order to give a pragmatic applicability of our findings, we examined which 
factor may allow excluding patients with an excessive risk of unreliable results on the 
basis of Doppler measurements of total hepatic blood flow, that we arbitrarily set as 
difference of >20% (“clinically relevant difference”). In that regard, it is important to 
remark our finding that patients with excessive liver arterialization (i.e., a hepatic artery 
fraction of total liver blood flow > 40%) had a 90% chance of exhibiting such a 
clinically significant discrepancy and therefore, US-HBF should be considered 
unreliable in such patients. Even if we believe that this finding is reasonably robust, we 
acknowledge that it can be questioned until confirmed by independent studies. 
 
In conclusion, our data provide new evidence regarding the use of Doppler-US as a non-
invasive method to estimate hepatic blood flow. Future studies using the combination of 
Doppler-US and elastographic methods [24-26] for non-invasive assessment of changes 
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in intrahepatic haemodynamics (a new target for the treatment of portal hypertension 
[27]) should take into account the limitations of Doppler-US. 
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Table 1.  Main clinical, laboratory and hemodynamic features of the studied population 
(n=50). 
 Characteristic  
Age (yrs) 56 ± 9 
Gender, n (M/F) 33/17 
Body surface area (m2) 1.81 ± 0.16 
Etiology, n 
(HCV/HBV/alcohol/other) 
25/2/15/8 
Child-Pugh class (A/B/C) 26/13/11 
Child-Pugh score 7.0 ± 2.2 
Esoph. Varices 
(no/small/large) 
12/15/23 
MELD score 11 ± 4 
Treatment with beta-blockers, n (%) 13 (26%) 
Ascites, n (%) 18 (36%) 
Previous decompensation, n (%) 22 (44%) 
Bilirubin (mg/dl) 1.8 ± 1.4 
INR 1.29 ± 0.25 
Albumin (g/dl) 3.6 ± 0.7 
Creatinine (mg/dl) 0.98 ± 0.23 
Platelets (n3/mmc) 115 ± 63 
Spleen diameter (cm) 14.9 ± 2.8 
HVPG (mmHg) 16.6 ± 6.0 
ICG hepatic clearance (ml/min) 208 ± 127 
ICG extraction index (%) 38 ± 23 
Mean arterial pressure (mmHg) 90 ± 14 
Heart rate (beats per minute) 74 ± 15 
  
 
 
18 
Table 2.  Results of DUS examination and ICG-HBF in the studied population. Data are  
 given overall and according to Child-Pugh classes as mean ± standard deviation. 
Parameter measured 
 
Overall (n=50) Child A 
(n=26) 
Child B 
(n=13) 
Child C 
(n=11) 
Diameter (mm) 
 
12.4±2.4 12.0±2.8 13.8±1.4 11.7±1.7 
Time averaged  
maximal velocity  
(cm/sec) 
16.5±5.6 17.0±5.0 17.5±6.2 14.2±5.9 
Volume of flow 
(ml/min) 
 
715±349 685±309 895±383 574±340 
Congestion index 
 
0.14±0.06 0.13±0.07 0.16±0.07 0.14±0.04 
Portal 
vein 
% of total blood 
flow 
 
72.6±16.8 71.4±15.6 77.9±18.5 68.5±17.4 
Diameter (mm) 
 
4.0±1.2 4.2±1.3 3.9±1.3 3.6±0.5 
Time averaged 
maximal velocity 
(cm/sec) 
36.3±19.3 34.8±12.7 39.4±31.3 36.3±15.3 
Volume of flow 
(ml/min) 
 
274±286 288±320 283±319 225±127 
Hepatic 
artery 
% of total blood 
flow 
 
27.4±16.8 28.6±15.6 22.1±18.6 31.5±17.4 
US-HBF 
(ml/min) 
 
 
994±494 
 
 
973±533 1177±448 807±402 
ICG-HBF 
(ml/min)  
1004±543 
 
 
843±345 1212±672 1147±344 
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Table 3.  Correlation of US findings and ICG-HBF with HVPG, Child-Pugh score and 
grade of esophageal varices. P values in bold are statistically significant (<0.05). 
 
 
Correlation 
with 
HVPG 
(R) 
 
p 
Correlation 
with 
 Child-
Pugh score 
(R) 
 
p 
Correlati
on with 
EV 
(no/Small
/Large) 
(R) 
 
p 
 
Diameter (mm) 
 
0.111 0.419 -0.026 0.851 0.574 <0.001 
Time averaged  
maximal velocity  
(cm/sec) 
-0.230 0.091 -0.260 0.049 -0.012 0.932 
Volume of flow 
(ml/min) 
 
-0.040 0.769 -0.139 0.312 0.350 0.009 
Congestion index 
 
0.296 0.028 0.139 0.311 0.466 <0.001 
Portal 
vein 
% of total blood 
flow 
 
-0.111 0.430 -0.137 0.327 -0.272 0.049 
Diameter (mm) 
 
0.075 0.592 -0.073 0.602 0.204 0.143 
Time averaged 
maximal velocity 
(cm/sec) 
0.040 0.769 0.128 0.352 0.078 0.572 
Volume of flow 
(ml/min) 
 
0.057 0.685 0.006 0.964 0.102 0.467 
Hepatic 
artery 
% of total blood 
flow 
 
0.111 0.430 0.137 0.327 0.272 0.049 
US-HBF 
(ml/min) 
 
-0.005 0.970 -0.105 0.454 0.355 0.009 
ICG-HBF 
(ml/min)  
0.013 0.930 0.113 0.436 0.222 0.122 
HVPG (mmHg) 
 
--- --- 0.577 <0.001 0.249 0.021 
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Figure legends 
 
Figure 1. Magnitude of the difference (ml/min) observed between US-HBF and ICG-
HBF according to the highest HBF as measured by any of the two methods. 
 
Figure 2. Correlation between US-HBF and ICG-HBF in the studied patients. Panel A- 
Correlation between US-HBF and ICG-HBF in the whole population of the study 
(n=50; R=0.464; p<0.0001). Panel B-Correlation between US-HBF and ICG-HBF in 
patients with ICG extraction > 0.20 (n=33; R=0.651; p<0.0001). 
 
Figure 3. ROC curve plotting the HABF percentage of US-HBF to discriminate patients 
with discrepancies between US-HBF and ICG-HBF  20% (AUROC 0.711; 95% CI 
0.533-0.892; p=0.043). The circle identifies the 90% specific cut-off chosen, consisting 
in a HABF component of over 40% of US-HBF. 
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